title: Oxidative stress parameters in women with breast cancer undergoing neoadjuvant chemotherapy and treated with nutraceutical doses of oral glutamine.
abstract: OBJECTIVE
  To evaluate the effects of oral administration of GLN on the oxidative stress in women with breast cancer undergoing neoadjuvant FAC chemotherapy (5 fluouracil 500 mg/m²+Doxorubicin 50 mg/m²+Cyclophosphamide 500 mg/m² body surface area).
  
  
  METHODS
  Twenty women (mean age: 51.7 years) with breast ductal carcinomas classified as T3 or T4 were included in the study, regardless of pre or post menopause status. Sachets containing glutamine 15g ("A") or milk protein 15g ("B") were prepared by a registered pharmacist. Allocation of patients was made by software program. Patients who received sachets labeled "A" were included in G1 group. The remaining patients, treated with the preparation labeled "B", were included in group G2. Sachets contents were blended in 150 ml of drinking water, and were given daily to each patient during the entire course of neoadjuvant chemotherapy. Peripheral blood samples were collected in the first day of each of the three cycles of chemotherapy before drug infusion. Tumor and normal breast samples were collected at the end of Patey´s surgical procedure. Samples were analysed for GSH and TBARS contents.
  
  
  RESULTS
  TBARS and GSH values were not different in breast healthy and tumor tissues nor blood when comparing control (G-2) and glutamine-treated (G-1) patients. Also, no significant differences were found in TBARS and GSH levels comparing different timepoints within the same group.
  
  
  CONCLUSIONS
  Oral GLN (15g/kg/day) offers no protection against systemic or local oxidative stress in women with breast Ca undergoing neoadjuvant chemotherapy (FAC).
authors.affiliation: Experimental Surgery Research Laboratory (LABCEX), Department of Surgery, Federal University of Ceara, Fortaleza-CE, Brazil.
authors.forename: José Wilson Mourão de
authors.initials: JW
authors.lastname: Farias
authors.forename: Flavia Siqueira
authors.initials: FS
authors.lastname: Furtado
authors.forename: Sergio Botelho
authors.initials: SB
authors.lastname: Guimarães
authors.forename: Antônio Ribeiro da
authors.initials: AR
authors.lastname: Silva Filho
authors.forename: Paulo Roberto Leitão de
authors.initials: PR
authors.lastname: Vasconcelos
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004311:Double-Blind Method; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005973:Glutamine / Q000008:administration & dosage*; D005978:Glutathione / Q000097:blood; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D018384:Oxidative Stress / Q000187:drug effects*; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D013997:Time Factors
chemical_list: D017392:Thiobarbituric Acid Reactive Substances; D005973:Glutamine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005978:Glutathione; D005472:Fluorouracil